[Results of a multi-center, international clinical trial of difluocortolone valerate (Nerisona)].

The new corticosteroid diflucortolone valerate was clinically investigated in an international, multi-centre trial by a total of 162 dermatologists in 22 countries in more than 6,285 patients with inflammatory and allergic skin diseases. Depending on the condition of the skin, diflucortolone valerate was applied as a cream, ointment or fatty ointment at a concentration of 0.1%. Most of the patients treated with the cream displayed weeping skin conditions. The ointment was used mainly in patients with neither weeping nor very dry skin conditions, while the fatty ointment was employed mainly in very dry processes. After the exclusion of invalid record forms, 5,578 cases remained for computer evaluation. The results confirm that the success rate in local corticoid therapy can be improved by adapting the base to the respective skin condition. The forms investigated were found to be highly effective preparations with excellent skin tolerance. They can be placed on a par with today's leading topical corticoid preparations.